Amgen, Generate Biomedicines sign $1.9bn worth research collaboration deal
Amgen has signed a research collaboration deal worth up to $1.9 billion with Cambridge-based Generate Biomedicines for the discovery and development of protein therapeutics for ... Read More
LUMAKRAS FDA approval : Amgen bags approval in KRAS G12C-mutated NSCLC
LUMAKRAS FDA approval : Amgen has bagged accelerated approval from the US Food and Drug Administration (FDA) for LUMAKRAS (sotorasib) for the treatment of a ... Read More
Amgen secures breakthrough therapy designation for sotorasib in China
Amgen has achieved a major milestone in the global development of its investigational KRAS G12C inhibitor, sotorasib, with the National Medical Products Administration (NMPA) in ... Read More
Janssen, Amgen secure FDA approval for DKd regiment in multiple myeloma
DKd regiment FDA approval for multiple myeloma : Janssen Pharmaceutical Companies of Johnson & Johnson and Amgen have been granted an expanded approval from the ... Read More
Amgen, Allergan file BLA to FDA for Rituxan biosimilar ABP 798
Rituxan biosimilar ABP 798 : US biopharma company Amgen and Irish pharma company Allergan have submitted a Biologics License Application (BLA) to the US Food ... Read More
CANDOR clinical trial results : Amgen’s Kyprolis extends PFS in multiple myeloma patients
CANDOR clinical trial results : Amgen said that a phase 3 study assessing Kyprolis (carfilzomib) in combination with dexamethasone and Johnson & Johnson's Darzalex (daratumumab) ... Read More
Amgen submits BLA for Infliximab biosimilar ABP 710 to FDA
Amgen Inc. has officially submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to ... Read More
FDA approves once-weekly dosing for Amgen’s Kyprolis in multiple myeloma treatment
The United States Food and Drug Administration (FDA) has granted approval for a new once-weekly dosing regimen of Amgen's Kyprolis (carfilzomib) in combination with dexamethasone ... Read More
AstraZeneca and Amgen secure FDA breakthrough designation for asthma drug tezepelumab
In a significant advancement for asthma treatment, AstraZeneca, in partnership with Amgen, has received the coveted breakthrough therapy designation from the US Food and Drug ... Read More
EC grants expanded approval for Amgen’s BLINCYTO in pediatric acute lymphoblastic leukemia treatment
In a significant development for pediatric oncology, the European Commission (EC) has approved an expanded indication for Amgen’s BLINCYTO (blinatumomab) as a monotherapy treatment for ... Read More